Nuveen LLC Takes $546,000 Position in Monte Rosa Therapeutics, Inc. $GLUE

Key Points

• Nuveen LLC acquired 117,672 shares of Monte Rosa Therapeutics, valued at approximately $546,000, representing 0.19% ownership as of its latest SEC filing.
• Monte Rosa Therapeutics has received a recent downgrade from a "buy" rating to a "hold" rating by Wall Street Zen, despite having two other analysts rate it as a "buy."
• The company's quarterly earnings showed a revenue of $23.19 million, significantly exceeding the consensus estimate of $7.23 million, with an EPS of ($0.15), beating the anticipated ($0.31).

Nuveen LLC bought a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 117,672 shares of the company's stock, valued at approximately $546,000. Nuveen LLC owned 0.19% of Monte Rosa Therapeutics as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Tower Research Capital LLC TRC raised its position in shares of Monte Rosa Therapeutics by 192.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,443 shares of the company's stock worth $38,000 after acquiring an additional 3,584 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Monte Rosa Therapeutics in the fourth quarter worth approximately $43,000. Focus Partners Wealth bought a new stake in Monte Rosa Therapeutics in the fourth quarter worth approximately $77,000. ProShare Advisors LLC acquired a new position in Monte Rosa Therapeutics in the fourth quarter valued at approximately $101,000. Finally, Invesco Ltd. boosted its holdings in shares of Monte Rosa Therapeutics by 175.1% during the 1st quarter. Invesco Ltd. now owns 35,346 shares of the company's stock worth $164,000 after buying an additional 22,499 shares in the last quarter. Institutional investors own 79.96% of the company's stock.

Monte Rosa Therapeutics Stock Down 0.6%

NASDAQ:GLUE traded down $0.03 on Wednesday, hitting $4.80. The stock had a trading volume of 379,828 shares, compared to its average volume of 334,073. Monte Rosa Therapeutics, Inc. has a 52 week low of $3.50 and a 52 week high of $12.40. The business's fifty day moving average is $4.97 and its 200 day moving average is $4.90. The company has a market cap of $296.45 million, a PE ratio of 13.33 and a beta of 1.42.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.16. The company had revenue of $23.19 million for the quarter, compared to analysts' expectations of $7.23 million. Monte Rosa Therapeutics had a return on equity of 9.95% and a net margin of 13.58%. Equities analysts predict that Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered shares of Monte Rosa Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $15.33.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.